Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Phagenesis Ltd logo — Dysphagia therapy like no other!

Phagenesis Ltd

Dysphagia therapy like no other!

Founded 2007 United Kingdom Manchester, United Kingdom 44 employees Series D Total: $68.00M Biotechnology, Health Care

General Information

Company Name Phagenesis Ltd
Founded Year 2007
Location United Kingdom Manchester, United Kingdom
Employees 44
Industries Biotechnology, Health Care
Funding Stage Series D
Social

BounceWatch is an independent company data service, not affiliated with Phagenesis Ltd. To contact Phagenesis Ltd, visit phagenesis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Phagenesis Ltd

Phagenesis Ltd is a UK-based biotechnology company focused on revolutionizing dysphagia treatment. Founded in 2007, their mission is to improve the lives of millions affected by dysphagia, a condition impairing swallowing function. Their flagship product, the Phagenyx, utilizes Pharyngeal Electrical Stimulation (PES) to restore swallowing control. Backed by a $42.00M Series D investment in March 2024 from notable investors including Aphelion Capital, British Patient Capital, Sectoral Asset Management, Northern Gritstone, and EQT Life Sciences, Phagenesis is committed to advancing dysphagia care through innovative technology and evidence-based practices. Their non-invasive, clinically-tested solution has demonstrated significant improvements in patients' swallowing abilities. As pioneers in this space, Phagenesis invites stakeholders to join their journey in reshaping dysphagia care and to stay updated on their impactful contributions.

Taxonomy: Dysphagia therapy, Pharyngeal Electrical Stimulation, Medical devices, Neuro-rehabilitation, Clinical trials, Innovative therapy, Neuroplasticity, Stroke recovery, Neurological disorders, Evidence-based practices, Neuroscience research, Healthcare innovation

Services & Products

Development and commercialization of the Pharyngeal Electrical Stimulation (PES) system for dysphagia treatment.

Target Customers

Healthcare providers hospitals rehabilitation centers and patients suffering from dysphagia.

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series D $42.00M 5
Aphelion Capital British Patient Capital Sectoral Asset Management
Aphelion Capital, British Patient Capital +3
04 Mar 2024
Non Equity Assistance Undisclosed 1
MedTech Innovator
MedTech Innovator
07 Jun 2022
Series B $17.00M 1
Inventages
Inventages
22 May 2013
Series B €7.00M 1
Inventages
Inventages
04 Oct 2011
Series A £2.00M -
01 Sep 2010

Phagenesis Ltd Alternatives & Competitors

View All Alternatives
Phagenesis Ltd vs
BioAxone Therapeutic, Inc.
BioAxone Therapeutic, Inc.

Pioneering neuroscience solutions with breakthrough therapies for neurological disorders, including...

Series B
2 employees
Biotechnology, Health Care
Phagenesis Ltd vs
Corlieve Therapeutics
Corlieve Therapeutics France

At Corlieve, we are focused on bringing novel therapeutic options to patients with severe neurologic...

Seed
1 employees
Biotechnology, Health Care
Phagenesis Ltd vs
RogCon, Inc.
RogCon, Inc. United States

The SCN2A Company

7 employees
Biotechnology, Health Care
View all alternatives

FAQ About Phagenesis Ltd

Dysphagia therapy like no other!
Phagenesis Ltd was founded in 2007.
Phagenesis Ltd is headquartered in Manchester, United Kingdom.
Phagenesis Ltd operates in Biotechnology and Health Care. Its work centres on Dysphagia therapy, Pharyngeal Electrical Stimulation, Medical devices and Neuro-rehabilitation. Its customers include Healthcare providers, hospitals and rehabilitation centers.
Phagenesis Ltd has approximately 44 employees.
Phagenesis Ltd has completed 5 funding rounds, raising a total of $68.00M. The latest funding stage is Series D.
Phagenesis Ltd offers: Development and commercialization of the Pharyngeal Electrical Stimulation (PES) system for dysphagia treatment..
Top alternatives and competitors to Phagenesis Ltd include BioAxone Therapeutic, Inc., Corlieve Therapeutics, RogCon, Inc., Comphya, Manus Neurodynamica. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Phagenesis Ltd and BioAxone Therapeutic, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Phagenesis Ltd, https://bouncewatch.com/company/phagenesis-ltd, updated 24 February 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes